mTOR

Open Access
Cancer Stem Cells in Glioblastoma: The Role of the mTOR Pathway
MONICA C. MUREB, SABRINA L. ZELLER, HAYLEN T. ROSBERGER, ERIS SPIROLLARI, MOHAN DAS, SIMON J. HANFT, CHIRAG D. GANDHI and MEENA JHANWAR-UNIYAL

Anticancer Research July 2025, 45 (7) 2697-2709; DOI: https://doi.org/10.21873/anticanres.17640
Open Access
Reduced Malignancy of Super Methotrexate-resistant Osteosarcoma Cells With Dihydrofolate Reductase Amplification Despite Paradoxical Gain of Oncogenic PI3K/AKT/mTOR and c-MYC expression
YUSUKE AOKI, YUTARO KUBOTA, NORIYUKI MASAKI, KOYA OBARA, YASUNORI TOME, MICHAEL BOUVET, KOTARO NISHIDA and ROBERT M. HOFFMAN

Anticancer Research July 2024, 44 (7) 2787-2792; DOI: https://doi.org/10.21873/anticanres.17090
You have access
Down-regulation of ABCB1 in Everolimus-resistant Renal Cell Carcinoma Cells
YUKO NAKAYAMA, AYA INO, KAZUHIRO YAMAMOTO and KOHJI TAKARA

Anticancer Research July 2024, 44 (7) 2871-2876; DOI: https://doi.org/10.21873/anticanres.17099
You have access
A Potential Combination of Targeting HSP90 and mTOR in Breast Cancer Cell Growth, Migration, and Invasion Through Inhibiting AKT Phosphorylation and F-actin Organization
PRASIT SUWANNALERT, PIMCHANOK PANPINYAPORN, PITCHAPA WANTANACHAISAENG, TEERAPAT TEEPPAIBUL, WILUNPLUS KHUMSRI, THIDARAT KOOMSANG, WITCHUDA PAYUHAKRIT and CHONNAPAT NAKTUBTIM

Anticancer Research June 2024, 44 (6) 2555-2565; DOI: https://doi.org/10.21873/anticanres.17061
Open Access
Selective Synergy of Rapamycin Combined With Methioninase on Cancer Cells Compared to Normal Cells
DANIEL ARDJMAND, YUTARO KUBOTA, MOTOKAZU SATO, QINGHONG HAN, KOHEI MIZUTA, SEI MORINAGA and ROBERT M. HOFFMAN

Anticancer Research March 2024, 44 (3) 929-933; DOI: https://doi.org/10.21873/anticanres.16887
Open Access
Molecular Characteristics of Everolimus-resistant Renal Cell Carcinoma Cells Generated by Continuous Exposure to Everolimus
YUKO NAKAYAMA, DAICHI ENOMOTO, KAZUHIRO YAMAMOTO and KOHJI TAKARA

Anticancer Research October 2023, 43 (10) 4349-4357; DOI: https://doi.org/10.21873/anticanres.16630
You have access
Unlocking Synergistic Potential: Enhancing Regorafenib Efficacy in Hepatocellular Carcinoma Through Combination Therapy With 18β-Glycyrrhetinic Acid
JR-DI YANG, PO-FU YUEH, TSAI LAN LIAO, YING-TZU CHEN, FEI-TING HSU, I-TSANG CHIANG, CHING MING CHANG and WEI-SHU WANG

Anticancer Research October 2023, 43 (10) 4403-4412; DOI: https://doi.org/10.21873/anticanres.16636
You have access
Combined Targeting of AKT and mTOR Synergistically Inhibits Formation of Primary Colorectal Carcinoma Tumouroids In Vitro: A 3D Tumour Model for Pre-therapeutic Drug Screening
DOMINIK NÖRZ, CHRISTINA S. MULLINS, DANIEL J. SMIT, MICHAEL LINNEBACHER, GRITH HAGEL, ALP MIRDOGAN, JACQUELINE SIEKIERA, PATRICK EHM, JAKOB R. IZBICKI, ANDREAS BLOCK, OLE THASTRUP and MANFRED JÜCKER

Anticancer Research May 2021, 41 (5) 2257-2275; DOI: https://doi.org/10.21873/anticanres.15002
You have access
Mir-139 Regulates Autophagy in Prostate Cancer Cells Through Beclin-1 and mTOR Signaling Proteins
ROBERT K. NAM, TANIA BENATAR, YUTAKA AMEMIYA, CHRISTOPHER SHERMAN and ARUN SETH

Anticancer Research December 2020, 40 (12) 6649-6663; DOI: https://doi.org/10.21873/anticanres.14689
You have access
Mitochondrial Glutamine Metabolism Determines Senescence Induction After Chemotherapy
BYUNGJOO KIM, JIHYE GWAK, EUN KYUNG LEE and SEUNG MIN JEONG

Anticancer Research December 2020, 40 (12) 6891-6897; DOI: https://doi.org/10.21873/anticanres.14712

Main menu

User menu

Search

mTOR

Pages